

P.L. 2025, CHAPTER 294, *approved January 20, 2026*
Senate, No. 1965 (*First Reprint*)

1 **AN ACT** concerning long-term care facilities and pharmaceutical
2 services and supplementing Title 26 of the Revised Statutes.

3
4 **BE IT ENACTED** *by the Senate and General Assembly of the State*
5 *of New Jersey:*

6
7 1. a. As used in this act:

8 "Long-term care facility" means a ¹**["nursing home, assisted living**
9 residence, comprehensive personal care home, residential health care
10 facility, or dementia care home licensed pursuant to P.L.1971, c.136
11 (C.26:2H-1 et seq.)**"] facility or distinct part of a facility licensed by**
12 the New Jersey Department of Health as a long-term care facility¹.

13 "Pharmacist" means a pharmacist licensed pursuant to P.L.2003,
14 c.280 (C.45:14-40 et seq.)

15 b. Each long-term care facility shall have a consultant pharmacist
16 and either a provider pharmacist or, if the facility has an in-house
17 pharmacy, a director of pharmaceutical services.

18 c. A New Jersey licensed pharmacist shall serve as director of
19 pharmaceutical services or as consultant pharmacist. The pharmacist
20 shall comply with federal and State statutes, rules, regulations, and
21 currently accepted standards of practice.

22 d. Each long-term care facility shall have an interdisciplinary
23 pharmacy and therapeutics committee, appointed by and reporting to
24 the facility's administrator and consisting of at least the administrator,
25 a representative of the nursing staff, and the facility's consultant
26 pharmacist, with oversight as needed by the facility's medical director.
27 The committee may include a licensed pharmacist representing the
28 provider pharmacy. The committee shall hold meetings at least
29 quarterly. Records, including the dates of meetings, attendance,
30 activities, findings, and recommendations, shall be maintained by the
31 committee.

32 e. Each long-term care facility shall appoint a consultant
33 pharmacist who is not also the director of pharmaceutical services or
34 pharmacist provider, and who attests that he or she does not have an
35 affiliation with either the facility's director of pharmaceutical services
36 or the facility's pharmacist provider. Following the appointment of
37 the consultant pharmacist, the consultant pharmacist shall avoid all

EXPLANATION – Matter enclosed in bold-faced brackets **[thus]** in the above bill is
not enacted and is intended to be omitted in the law.

Matter underlined thus is new matter.

Matter enclosed in superscript numerals has been adopted as follows:

¹Senate SHH committee amendments adopted March 14, 2024.

1 real or potential conflicts of interest with the facility's director of
2 pharmaceutical services or the facility's pharmacist provider.

3 f. If a long-term care facility keeps emergency injectable or oral
4 controlled substances, the facility shall ensure that a current Drug
5 Enforcement Administration registration and controlled dangerous
6 substance registration for that location is available.

7

8 2. The Commissioner of Health shall adopt rules and
9 regulations, in accordance with the "Administrative Procedure Act,"
10 P.L.1968, c.410 (C.52:14B-1 et seq.), as are necessary to effectuate
11 the provisions of this act.

12

13 3. This act shall take effect immediately.

14

15

16

17

18 Regulates provision of pharmaceutical services in long-term care
19 facilities.